Kennondale Capital Management LLC Akero Therapeutics, Inc. Transaction History
Kennondale Capital Management LLC
- $91.7 Billion
- Q1 2025
A detailed history of Kennondale Capital Management LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Kennondale Capital Management LLC holds 14,108 shares of AKRO stock, worth $762,396. This represents 0.62% of its overall portfolio holdings.
Number of Shares
14,108
Previous 28,217
50.0%
Holding current value
$762,396
Previous $785 Million
27.25%
% of portfolio
0.62%
Previous 0.85%
Shares
2 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$401 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$382 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$321 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$302 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$283 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.51B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...